The pipeline for new pain drugs has grown perilously thin in recent years with a slate of key clinical trial failures. Only a few small players are still actively engaged in developing new therapies to replace the aging therapeutics that now dominate the market, especially after Pfizer’s last setback on an anti-NGF drug, finally closing that chapter of new drug development. Endpoints News will take a close look at the conditions that are limiting access to new drugs and the intense medical need to find drugs that can do a better job for an aging population. Lei Lei Wu will dig in to explain what’s happening here.
Jeffrey S. Mogil is currently the E.P. Taylor Professor of Pain Studies and the Canada Research Chair in the Genetics of Pain at McGill University, and the past Director of the Alan Edwards Centre for the Study of Pain. Dr. Mogil has made seminal contributions to the field of pain genetics and is the author of many major reviews of the subject, including an edited book, The Genetics of Pain (IASP Press, 2004). He is also a recognized authority in the fields of sex differences in pain and analgesia, and pain testing methods in the laboratory mouse. Dr. Mogil is the author of over 270 journal articles and book chapters since 1992 and has given almost 400 invited lectures in that same period. His h-index is currently 91. He has trained almost 30 graduate students, postdocs, and visiting scholars, over 170 undergraduate research assistants, and lectures on pain to over 400 undergraduates every year. He is the recipient of numerous awards, including: the Neal E. Miller New Investigator Award from the Academy of Behavioral Medicine Research; the Patrick D. Wall Young Investigator Award from the International Association for the Study of Pain; the SGV Award from the Swiss Laboratory Animal Science Association; the Donald O. Hebb Award from the Canadian Psychological Association; the John C. Liebeskind (early career) and Frederick W.L. Kerr (lifetime achievement) awards from the American Pain Society; and Early Career, Distinguished Career, and Outstanding Mentorship awards from the Canadian Pain Society. He recently served as a Councilor at IASP and was the Chair of the Scientific Program Committee of the 13 th World Congress on Pain.
Dr. Michael L. Oshinsky is the Director of the NINDS Office of Preclinical Pain Research. Before joining NINDS, he was on the faculty in the Department of Neurology at Thomas Jefferson University for 14 years. In 2011, Dr. Oshinsky was award the Harold G. Wolff Award for headache research. As Director of the NINDS Office of Preclinical Pain Research, Dr. Oshinsky is responsible for translational and basic science research related to migraine, other headache disorders, neuropathic pain, peripheral and central mechanisms that mediate pain, central processing of pain perception, disease-related pain disorders, and pain management.
Mark A. Mintun, MD has been the Vice-President of Pain and Neurodegeneration Research and Clinical Development since January of 2018 and Senior Vice-President of Neuroscience since October of 2021. In 2010, Dr. Mintun joined Avid Radiopharmaceuticals, a wholly-owned subsidiary of Eli Lilly & Co., as Chief Medical Officer and became its President in 2014. Prior to Avid, Dr. Mintun was Professor and Vice-Chair of Radiology at the Mallinckrodt Institute of Radiology at the Washington University School of Medicine, with joint appointments in Psychiatry, Neurology, Bioengineering, and the Anatomy and Neurobiology Departments. He earned a BS in Chemical Engineering from the Massachusetts Institute of Technology in 1977, received his medical degree in 1981 at Washington University School of Medicine and completed a research fellowship in neurology and residency training in nuclear medicine. Dr. Mintun has co-authored over 200 research publications that include reports of brain imaging to characterize flow/metabolism relationships, neurotransmitter systems, circuitry for processing affective stimuli and the pathology of neurodegenerative diseases. After joining Avid he led development programs for both amyloid and tau imaging of patients with neurodegenerative diseases. More recently he has overseen the extensive research and early phase development programs for Alzheimer disease, Parkinson disease, Migraine and Chronic Pain conditions.
Jennifer Gewandter, PhD, MPH is an Associate Professor in the Department of Anesthesiology and Perioperative Medicine at the University of Rochester and an Associate Director of the FDA Public-Private partnership, ACTTION. Her research and scholarly activities are focused on optimizing the design, execution, and transparent dissemination of clinical trials for pain and peripheral neuropathy treatments as well as researching interventions for chemotherapy-induced peripheral neuropathy and chronic low back pain. She is a Co-PI of the University of Rochester’s Clinical Hub of the NIH-funded Early Phase Pain Investigation Clinical Network (EPPIC-Net) and is the PI of an NIH-funded, multi-site RCT of a TENS intervention for CIPN. She has co-authored over 75 peer-reviewed publications including those published in PAIN, The Journal of Pain, and Neurology and she served as a co-section editor of the Neuropathic Pain Section of Pain Medicine. She has mentored over 20 medical students, residents, fellows, and clinical faculty in research design and scientific writing.
Always driven to improve patients’ lives, Jan Adams has built up more than 15 years of experience in healthcare and biopharmaceuticals and took over the role of CSO in 2020. Under his leadership, Grünenthal transformed its R&D strategy and operating model and significantly strengthened its pipeline of highly innovative non-opioid pain assets.
Jan joined Grünenthal in July 2017 as Head of Corporate Strategy and Portfolio Management, working at the interface between strategy, research, development and commercial. Prior to joining Grünenthal, he served in roles with increasing levels of responsibility at Novartis and Takeda, as well as within McKinsey & Company’s global Pharmaceutical and Medical Products practice.